This document provides an overview of aortic stenosis, including its epidemiology, anatomy, causes, pathophysiology, and clinical presentation. Some key points:
- Aortic stenosis is narrowing of the aortic valve that obstructs blood flow from the left ventricle. It most commonly results from calcification of the aortic valve.
- The rate of progression from early valve changes to severe stenosis is typically 1.8-1.9% per year in those over 75, 3.4% have severe stenosis.
- As stenosis progresses, the left ventricle undergoes hypertrophic remodeling to maintain cardiac output, but this impairs diastolic function over time.
- Stages of
3. Introduction
Aortic stenosis (AS) is narrowing of the
aortic valve, obstructing blood flow from
the left ventricle to the ascending aorta
during systole.
3
4. Epidemiology
In recent population-based
echocardiographic studies, 1% to 2% of
persons age 65 or older and 12% of persons
75 or older had calcific aortic stenosis
4
5. Epidemiology
The rate of progression from aortic sclerosis
to stenosis is 1.8% to 1.9% per year.
Among those older than 75, 3.4% (95%
confidence interval [CI] 1.1% to 5.7%) have
severe AS
5
6. Epidemiology
The rate of progression from aortic sclerosis
to stenosis is 1.8% to 1.9% per year.
Among those older than 75, 3.4% (95%
confidence interval [CI] 1.1% to 5.7%) have
severe AS
6
14. Causes and Pathology
Valvular AS has three principal causes:
1. congenital bicuspid valve with superimposed
calcification,
2. calcification of a normal trileaflet valve, and
3. rheumatic disease
14
15. Causes and Pathology
Valvular AS has three principal causes:
1. congenital bicuspid valve with superimposed
calcification,
2. calcification of a normal trileaflet valve, and
3. rheumatic disease
15
16. Causes and Pathology
In addition,
congenital valve stenosis manifesting in
infancy or childhood
Rarely, AS is caused by severe
atherosclerosis of the aorta and aortic valve
this form of AS occurs most frequently in
patients with severe hypercholesterolemia and
is observed in children with homozygous type
II hyperlipoproteinemia 16
17. Causes and Pathology
Hypertension is a major cause of Aortic
stenosis
Hypertension has been shown to be
independently associated with degenerative
calcific aortic valve sclerosis and stenosis in
elderly population.
HTA - Wall shear stress – Aortic sclerosis –
valve calcification. 17
18. Causes and Pathology
Rheumatoid involvement of the valve is a
rare cause of AS and results in nodular
thickening of the valve leaflets and
involvement of the proximal portion of the
aorta.
Ochronosis (accumulation of homogentisic
acid in connective tissues - Arthrits) with
alkaptonuria is another rare cause of AS. 18
20. Causes and Pathology
Rheumatoid involvement of the valve is a
rare cause of AS and results in nodular
thickening of the valve leaflets and
involvement of the proximal portion of the
aorta.
Ochronosis (accumulation of homogentisic
acid in connective tissues - Arthrits) with
alkaptonuria is another rare cause of AS. 20
21. Causes and Pathology
Fixed obstruction to left ventricular (LV)
outflow also may occur above the valve
(supravalvular stenosis) or below the valve
(discrete subvalvular stenosis)
21
22. Causes and Pathology
Congenital Aortic Valve Disease
Congenital malformations of the aortic valve
may be unicuspid, bicuspid, or tricuspid, or the
anomaly may manifest as a dome-shaped
diaphragm.
22
24. Causes and Pathology
Calcific Aortic Valve Disease
Calcific (formerly “senile” or “degenerative”) aortic
valve disease affecting a congenital bicuspid or
normal trileaflet valve is now the most common cause
of AS in adults.
24
25. Associations in Observational and Epidemiologic Studies of
Clinical Risk Factors and Calcific Aortic Valve Disease (CAVD)
25
26. Causes and Pathology
Calcific Aortic Valve Disease
Aortic sclerosis, identified by either
echocardiography or computed tomography
(CT), is the initial stage of calcific valve disease
and, even in the absence of valve obstruction
or known cardiovascular disease, is associated
with an increased risk of myocardial infarction
(MI) and cardiovascular and all-cause mortality
26
27. Causes and Pathology
Calcific Aortic Valve Disease
Aortic sclerosis, identified by either
echocardiography or computed tomography
(CT), is the initial stage of calcific valve disease
and, even in the absence of valve obstruction
or known cardiovascular disease, is associated
with an increased risk of myocardial infarction
(MI) and cardiovascular and all-cause mortality
27
28. Causes and Pathology
Calcific Aortic Valve Disease
Although calcific AS once was considered to
represent the result of years of normal
mechanical stress on an otherwise normal
valve (“wear and tear”), it is now clear that an
active biology underlies the initiation and
progression of calcific aortic valve disease
28
30. Causes and Pathology
Calcific Aortic Valve Disease
Although calcific AS once was considered to
represent the result of years of normal
mechanical stress on an otherwise normal
valve (“wear and tear”), it is now clear that an
active biology underlies the initiation and
progression of calcific aortic valve disease
30
31. Causes and Pathology
Calcific Aortic Valve Disease
Normal valve leaflets are comprised of the
fibrosa (facing the aorta), ventricularis (facing
the ventricle), and spongiosa (located between
the fibrosa and ventricularis)
Valve interstitial cells (VICs) are the most
predominant cell type; endothelial and smooth
muscle cells are also present
31
32. Causes and Pathology
Calcific Aortic Valve Disease
Through a complex interplay of molecular
events, the pliable, flexible valve becomes stiff
and immobile, characterized grossly by fibrosis
and calcification.
The process is initiated by lipid infiltration and
oxidative stress, which attract and activate
inflammatory cells and promote the elaboration
of cytokines. 32
33. Causes and Pathology
Calcific Aortic Valve Disease
VICs undergo osteogenic reprogramming that
promotes the mineralization of the extracellular
matrix and the progression of fibrocalcific
remodeling of the valve.
33
35. Causes and Pathology
Calcific Aortic Valve Disease
Familial clustering of calcific AS also has been
described, suggesting a possible genetic
predisposition to valve calcification
Genetic polymorphisms have been linked to the
presence of calcific AS, including those
involving the vitamin D receptor, interleukin
(IL)-10 alleles, estrogen receptor, transforming
growth factor (TGF)-ß receptor, and the
apolipoprotein E4 allele 35
36. Causes and Pathology
Rheumatic Aortic Stenosis
Rheumatic AS results from adhesions and
fusions of the commissures and cusps and
vascularization of the leaflets of the valve ring,
leading to retraction and stiffening of the free
borders of the cusps.
Calcific nodules develop on both surfaces, and
the orifice is reduced to a small, round or
triangular opening.
36
38. Causes and Pathology
Rheumatic Aortic Stenosis
Rheumatic AS results from adhesions and
fusions of the commissures and cusps and
vascularization of the leaflets of the valve ring,
leading to retraction and stiffening of the free
borders of the cusps.
Calcific nodules develop on both surfaces, and
the orifice is reduced to a small, round or
triangular opening.
38
39. Causes and Pathology
Rheumatic Aortic Stenosis
As a consequence, the rheumatic valve often is
regurgitant as well as stenotic. Patients with
rheumatic AS invariably have rheumatic
involvement of the mitral valve.
With the decline in rheumatic fever in
developed nations, rheumatic AS is decreasing
in frequency, although it continues to be a
major problem on a worldwide basis.
39
40. Age < 70 years
(n=324)
Age >70 years
(n=322)
1. Bicuspid AV(50%) Degenerative (48%)
(Hypertension)
2. Rheumatic (25%) Bicuspid (27%)
3. Degenerative (18%) Rheumatic (23%)
4. Unicommissural (3%) Hypoplastic (2%)
5. Hypoplastic (2%)
6. Indeterminate (2%)
Causes
41.
42. Calcific Aortic
Stenosis
Nodular calcific masses on aortic
side of cusps.
No commissural fusion.
Free edges of cusps are not
involved.
Stellate-shaped systolic orifice.
44. Parasternal short-axis
view showing calcified
aortic valve leaflets.
Immobility of the cusps
results in only a slit like
aortic valve orifice in
systole
46. Two cusps are seen in systole with only two
commissures framing an elliptical systolic
orifice.
Diastolic images may mimic a tricuspid valve
when a raphe is present.
47.
48. Parasternal long-axis echo
may Show an asymmetric
closure line systolic doming
Diastolic prolapse of the cusps
In children, valve may be Stenotic without extensive
calcification.
49. In adults, stenosis typically is due to calcific
changes, which often obscures the number of
cusps, making determination of bicuspid vs.
tricuspid valve difficult.
51. Parasternal short axis view showing
commissural fusion, leaflet thickening and
calcification, small triangular systolic orifice
52. Subvalvularaortic
stenosis
Thin discrete membrane consisting of
endocardial fold and fibrous tissue.
A fibromuscular ridge.
Diffuse tunnel-like narrowing of the LVOT.
Accessory or anomalous mitral valve tissue.
53. Supravalvular Aortic
stenosis
Type I -Thick, fibrous ring above the aortic valve
with less mobility and has the easily identifiable
'hourglass' appearance of the aorta.
54. Type II - Thin, discrete fibrous membrane
located above the aortic
valve.
The membrane usually mobile and may
demonstrate doming during systole.
Type III - Diffuse narrowing.
55. Pathophysiology
Valve Obstruction
In adults with calcific AS, a significant burden
of leaflet disease is present before obstruction
to outflow develops.
However, once even mild obstruction is
present, hemodynamic progression occurs in
almost all patients, with the interval from mild
to severe obstruction ranging from less than 5
to more than 10 years
55
57. Pathophysiology
Valve Obstruction
In adults with calcific AS, a significant burden
of leaflet disease is present before obstruction
to outflow develops.
However, once even mild obstruction is
present, hemodynamic progression occurs in
almost all patients, with the interval from mild
to severe obstruction ranging from less than 5
to more than 10 years
57
63. Pathophysiology
Valve Obstruction
The degree of stenosis associated with
symptom onset varies among patients,
however, and no single number defines severe
or critical AS in an individual patient.
63
64. Pathophysiology
Hypertrophic Myocardial Remodeling
Maintenance of cardiac output in the face of an
obstructed aortic valve imposes a chronic
increase in LV pressure
In response, the ventricle typically undergoes
hypertrophic remodeling characterized by
myocyte hypertrophy and increased wall
thickness
64
66. Pathophysiology
Hypertrophic Myocardial Remodeling
Based on LaPlace law, LV remodeling reduces
wall stress (afterload) and is considered one of
the important compensatory mechanisms to
maintain LV ejection performance, which is
directly affected by afterload
66
67. Pathophysiology
Hypertrophic Myocardial Remodeling
increased LV hypertrophic remodeling is
associated with more severe ventricular
dysfunction and heart failure (HF) symptoms,
as well as higher mortality
hypertrophic remodeling in patients with AS is
determined by several factors other than the
severity of valve obstruction, including sex,
genetics, vascular load, and metabolic
abnormalities 67
68. Pathophysiology
Hypertrophic Myocardial Remodeling
increased LV hypertrophic remodeling is
associated with more severe ventricular
dysfunction and heart failure (HF) symptoms,
as well as higher mortality
hypertrophic remodeling in patients with AS is
determined by several factors other than the
severity of valve obstruction, including sex,
genetics, vascular load, and metabolic
abnormalities 68
69. Pathophysiology
Left Ventricular Diastolic Function
Hypertrophic remodeling also impairs diastolic
myocardial relaxation and increases stiffness
Higher cardiomyocyte stiffness, increased
myocardial fibrosis, advanced-glycation end
products, and metabolic abnormalities each
contribute to increased chamber stiffness and
higher end-diastolic pressures.
69
70. Pathophysiology
Left Ventricular Diastolic Function
Hypertrophic remodeling also impairs diastolic
myocardial relaxation and increases stiffness
Higher cardiomyocyte stiffness, increased
myocardial fibrosis, advanced-glycation end
products, and metabolic abnormalities each
contribute to increased chamber stiffness and
higher end-diastolic pressures.
70
71. Pathophysiology
Left Ventricular Diastolic Function
Atrial contraction plays a particularly important
role in filling of the left ventricle in AS because
it increases LV end-diastolic pressure without
causing a concomitant elevation of mean left
atrial pressure.
71
72. Pathophysiology
Left Ventricular Diastolic Function
This “booster pump” function of the left atrium
prevents the pulmonary venous and capillary
pressures from rising to levels that would
produce pulmonary congestion, while
maintaining LV end-diastolic pressure at the
elevated level necessary for effective
contraction of the hypertrophied left ventricle.
72
73. Pathophysiology
Left Ventricular Diastolic Function
Loss of appropriately timed, vigorous atrial
contraction, as occurs in atrial fibrillation (AF)
or atrioventricular dissociation, may result in
rapid clinical deterioration in patients with
severe AS.
73
74. Pathophysiology
Left Ventricular Diastolic Function
After surgical relief of AS, diastolic dysfunction
may revert toward normal with regression of
hypertrophy, but some degree of long-term
diastolic dysfunction typically persists.
74
75. Pathophysiology
Left Ventricular Systolic Function
Left ventricular systolic function, as measured
by the ejection fraction (EF), remains normal
until late in the disease process in most
patients with AS.
Nonetheless, more subtle systolic dysfunction
can be detected as reduced longitudinal
systolic strain before a reduction in the EF
75
76. Pathophysiology
Left Ventricular Systolic Function
The development and severity of systolic
dysfunction is the result ;
the severity of valve obstruction,
metabolic abnormalities,
vascular load,
inadequate hypertrophy (given the
inverse correlation between wall stress and
systolic performance),
maladaptive hypertrophy (resulting in
impaired contractility),
ischemia, and fibrosis. 76
77. Pathophysiology
Myocardial Fibrosis
Cardiac fibrosis is an emerging risk factor for
adverse clinical outcomes in patients with AS
As a part of the hypertrophic remodeling
process, diffuse and replacement myocardial
fibrosis (not fibrosis from prior MI) may
develop.
77
78. Pathophysiology
Left Ventricular Systolic Function
Importantly, patients with severe fibrosis,
despite a normal EF, are more likely to have
worse preoperative HF symptoms and less
likely to experience improvement in symptoms
midterm after valve replacement, compared to
those with no or minimal fibrosis before valve
replacement
78
79. Pathophysiology
Pulmonary and Systemic Vasculature
The hypertrophied and pressure overloaded left
ventricle transmits increased pressure to the
pulmonary vasculature, which leads to
pulmonary hypertension in many patients with
AS, becoming severe in 15% to 20%.
pulmonary hypertension is associated with
increased postoperative mortality
79
80. Pathophysiology
Pulmonary and Systemic Vasculature
The hypertrophied and pressure overloaded left
ventricle transmits increased pressure to the
pulmonary vasculature, which leads to
pulmonary hypertension in many patients with
AS, becoming severe in 15% to 20%.
pulmonary hypertension is associated with
increased postoperative mortality
80
81. Pathophysiology
Myocardial Ischemia
In patients with AS, the hypertrophied left
ventricle, increased systolic pressure, and
prolongation of ejection all elevate myocardial
oxygen (O2) consumption.
81
82. Pathophysiology
Myocardial Ischemia
At the same time, even in the absence of
epicardial coronary disease, decreased
myocardial capillary density in the
hypertrophied ventricle, increased LV end-
diastolic pressure, and a shortened diastole all
serve to decrease the coronary perfusion
pressure gradient and myocardial blood flow.
82
84. Pathophysiology
Myocardial Ischemia
Exercise or other states of increased O2
demand may exacerbate this imbalance and
cause angina indistinguishable from that
caused by epicardial coronary obstruction.
84
86. Clinical Presentation
Symptoms
Symptoms typically begin at age 50 to 70 years
with bicuspid aortic valve stenosis and
in those older than 70 with calcific stenosis of a
trileaflet valve,
although even in this age group approximately
40% of patients with AS have a congenital
bicuspid valve
86
87. Clinical Presentation
Symptoms
The most common clinical presentation in
patients with a known diagnosis of AS who are
followed prospectively is a gradual decrease in
exercise tolerance, fatigue, or dyspnea on
exertion
87
88. Clinical Presentation
Symptoms
The mechanism of exertional dyspnea may be
LV diastolic dysfunction, with an excessive rise
in end-diastolic pressure leading to pulmonary
congestion
Alternatively, exertional symptoms may be a
result of the limited ability to increase cardiac
output with exercise.
88
89. Clinical Presentation
Symptoms
More severe exertional dyspnea, with
orthopnea,
paroxysmal nocturnal dyspnea, and
pulmonary edema,
reflects various degrees of pulmonary venous
hypertension
intervention typically is undertaken before this
disease stage.
89
90. Clinical Presentation
Symptoms
Angina is a frequent symptom of patients with
severe AS and usually resembles the angina
observed in patients with coronary artery
disease (CAD) in that it is usually precipitated
by exertion and relieved by rest
90
91. Clinical Presentation
Symptoms
In patients with CAD, angina is caused by a
combination of epicardial coronary artery
obstruction and the O2 imbalance characteristic
of AS.
Very rarely, angina results from calcific emboli
to the coronary vascular bed.
91
92. Clinical Presentation
Symptoms
Syncope most often is caused by the reduced
cerebral perfusion that occurs during exertion
when arterial pressure declines because of
systemic vasodilation and an inadequate
increase in cardiac output related to
valvular stenosis.
92
93. Clinical Presentation
Symptoms
Syncope most often is caused by the reduced
cerebral perfusion that occurs during exertion
when arterial pressure declines because of
systemic vasodilation and an inadequate
increase in cardiac output related to
valvular stenosis.
93
94. Clinical Presentation
Symptoms
Syncope also has been attributed to
malfunction of the baroreceptor mechanism in
severe AS, as well as to a vasodepressor
response to a greatly elevated LV systolic
pressure during exercise
Exertional hypotension also may be manifested
as “graying-out spells” or dizziness on effort
94
95. Clinical Presentation
Symptoms
Syncope at rest may be caused by transient
AF with loss of the atrial contribution to LV
filling, which causes a precipitous decline in
cardiac output, or to transient atrioventricular
(AV) block caused by extension of the
calcification of the valve into the conduction
system.
95
96. Clinical Presentation
Symptoms
Gastrointestinal (GI) bleeding may develop in
patients with severe AS, often associated with
angiodysplasia (most frequently of the right
colon) or other vascular malformations
This complication arises from shear stress–
induced platelet aggregation with a reduction
in high-molecular-weight multimers of von
Willebrand factor and increases in proteolytic
subunit fragments 96
97. Clinical Presentation
Symptoms
Infective endocarditis has been documented
in patients with aortic valve disease,
particularly in younger patients with a
bicuspid valve.
Cerebral emboli resulting in stroke or
transient ischemic attacks (TIAs) may be
caused by microthrombi on thickened
bicuspid valves.
97
99. Clinical Presentation
Physical Examination
The key features of the physical examination in
patients with AS are
palpation of the carotid upstroke,
evaluation of the systolic murmur,
assessment of splitting of the second heart
sound (S2),
signs of HF
99
100. Clinical Presentation
Physical Examination
The carotid upstroke directly reflects the
arterial pressure waveform. The expected finding
with severe AS is a
slow-rising, late-peaking, low-amplitude carotid
pulse, the parvus and tardus carotid impulse.
When present, this finding is specific for severe
AS.
100
102. Clinical Presentation
Physical Examination
Auscultation
The ejection systolic murmur of AS typically is
late-peaking and heard best at the base of the
heart, with radiation to the carotids.
Cessation of the murmur before A2 is helpful in
differentiation from a pansystolic mitral murmur.
102
103. Clinical Presentation
Physical Examination
Auscultation
In patients with calcified aortic valves, the
systolic murmur is loudest at the base of the
heart,
but high-frequency components may radiate
to the apex—the so-called Gallavardin
phenomenon, in which the murmur may be so
prominent that it is mistaken for the murmur of
mitral regurgitation (MR) 103
104. Clinical Presentation
Physical Examination
Auscultation
In general, a louder and later-peaking murmur
indicates more severe stenosis.
However, although a systolic murmur of grade 3
intensity or greater is relatively specific for severe
AS, this finding is insensitive, and many patients
with severe AS have only a grade 2 murmur
104
105. Clinical Presentation
Physical Examination
Auscultation
When the left ventricle fails and stroke volume
falls, the systolic murmur of AS becomes softer;
rarely, it disappears altogether.
105
106. Clinical Presentation
Physical Examination
Auscultation
With severe AS, S2 may be single because
calcification and immobility of the aortic valve
make A2 inaudible, (2) closure of the pulmonic
valve (P2) is buried in the
prolonged aortic ejection murmur, or (3)
prolongation of LV systole makes A2 coincide with
P2.
- Paradoxical splitting is also seen 106
107. Clinical Presentation
Dynamic Auscultation
Auscultation
The intensity of the systolic murmur varies from
beat to beat when the duration of diastolic filling
varies, as in AF or after a premature contraction.
This characteristic is helpful in differentiating AS
from MR, in which the murmur usually is
unaffected.
107
108. Clinical Presentation
Dynamic Auscultation
Auscultation
The murmur of valvular AS is augmented by
squatting, which increases stroke volume. It is
reduced in intensity during the strain of the
Valsalva maneuver and on standing, both of
which reduce transvalvular flow.
108
137. Exercise Stress Testing
Exercise testing may be helpful in apparently
asymptomatic patients to unmask symptoms or
demonstrate limited exercise capacity or an
abnormal BP response.
Exercise stress testing should be absolutely
avoided in symptomatic patients
137
138. Cardiac Computed Tomography
CT is also a routine part of the preprocedural
evaluation of patients having AVR, principally to
look for a porcelain aorta, as well as determine
appropriate valve sizing and assess aortic and
peripheral vascular anatomy when a
transcatheter approach is considered.
138
139. Cardiac Computed Tomography
CT is also a routine part of the preprocedural
evaluation of patients having AVR, principally to
look for a porcelain aorta, as well as determine
appropriate valve sizing and assess aortic and
peripheral vascular anatomy when a
transcatheter approach is considered.
139
140. Cardiac Computed Tomography
CT is useful for evaluating aortic dilation in
patients with evidence or suspicion of aortic
root disease on echocardiography or chest
radiography, particularly those with a bicuspid
valve
140
141. Cardiac Catheterization
Cardiac catheterization is now recommended
only when noninvasive tests are inconclusive,
when clinical and echocardiographic findings
are discrepant, and for coronary angiography
before surgical intervention
141
142. Cardiac Magnetic Resonance
Imaging
CMR is useful for assessing LV volume,
function, and mass, especially in settings where
this information cannot be obtained readily
from echocardiography
142
143. Positron Emission Tomography
(PET) identifies active tissue calcification and
predicts change in aortic valve calcification on
follow-up CT 1 to 2 years later
143
146. Treatment
1. Medical Management
Medical therapy has not been shown to affect
disease progression in patients with AS
treatment of hypertension
Angiotensin-converting-enzyme (ACE) inhibitors
or angiotensin receptor blockers (ARBs) may
preferentially considered. 146
147. Treatment
Medical Management
heart failure - diuretics.
phosphodiesterase type 5 inhibition - improve
pulmonary and systemic hemodynamics
147
149. Balloon Aortic Valvuloplasty
In selected cases, it might be reasonable as a
bridge to definitive treatment with AVR in
unstable patients or as a palliative procedure in
patients who are not candidates for AVR.
149
150. Aortic Valve Replacement
AVR is recommended for adults with
symptomatic severe AS, even if symptoms are
mild
150
152. Surgical Aortic Valve
Replacement
The Society of Thoracic Surgeons (STS)
National Database Committee reported an
overall operative mortality rate of 3.2% in
67,292 patients undergoing isolated AVR and
5.6% in 66,074 patients undergoing AVR and
CABG
152
160. Disease Course
Asymptomatic Patients
Generally, repeat imaging is performed every
6 to 12 months for severe AS,
every 1 to 2 years for moderate AS, and
every 3 to 5 years for mild AS,
unless a change in signs or symptoms prompts
repeat imaging sooner
160
161. Disease Course
Asymptomatic Patients
Generally, repeat imaging is performed every
6 to 12 months for severe AS,
every 1 to 2 years for moderate AS, and
every 3 to 5 years for mild AS,
unless a change in signs or symptoms prompts
repeat imaging sooner
161
162. Disease Course
Asymptomatic Patients
Of patients with mild valve thickening but no
obstruction to outflow (e.g., aortic sclerosis),
16% will have valve obstruction at 1 year of
follow-up, but only 2.5% will develop severe
valve obstruction at an average of 8 years
after the diagnosis of aortic sclerosis.
162
163. Disease Course
Asymptomatic Patients
Of patients with mild valve thickening but no
obstruction to outflow (e.g., aortic sclerosis),
16% will have valve obstruction at 1 year of
follow-up, but only 2.5% will develop severe
valve obstruction at an average of 8 years
after the diagnosis of aortic sclerosis.
163
164. Disease Course
Asymptomatic Patients
Survival free of symptoms is 84% at 2 years
when aortic velocity is less than 3 m/sec,
compared with only 21% when velocity is
greater than 4 m/sec
164
165. Disease Course
Asymptomatic Patients
exercise testing and serum B-type natriuretic
peptide (BNP) levels have been evaluated as
measures of disease progression and predictors
of symptom onset.
165
166. Disease Course
Symptomatic Patients
Once even mild symptoms are present, survival
is poor unless outflow obstruction is relieved.
average survival without AVR is only 1 to
3 years after symptom onset
166
167. Disease Course
Symptomatic Patients
Among symptomatic patients with severe AS,
the outlook is poorest when the left ventricle
has failed and the cardiac output and
transvalvular gradient are both low.
The risk of sudden death is high with
symptomatic severe AS, so these patients
should be promptly referred for AVR.
167
168. Disease Course
Symptomatic Patients
Among symptomatic patients with severe AS,
the outlook is poorest when the left ventricle
has failed and the cardiac output and
transvalvular gradient are both low.
The risk of sudden death is high with
symptomatic severe AS, so these patients
should be promptly referred for AVR.
168